Evidence map›Paper›PMID 35366263›Full record

ArticlePathophysiology : the official journal of the International Society for Pathophysiology2021

A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto's Thyroiditis and in Psoriasis: Study Protocol.

Evangelia Sarandi, Sabine Kruger Krasagakis, Dimitris Tsoukalas, Gottfried Rudofsky, Aristides Tsatsakis

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04693936 (Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04693936 naunknown statusnot on this map

Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis

TypeinterventionalSponsorUniversity of CreteRan2021 to 2024Enrolled200ConditionsHashimoto Disease, PsoriasisArmsNutraceutical Combination Plan
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Conundrum for Psoriasis and Thyroid Involvement.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Evangelia SarandiLaboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-3058-429X
Sabine Kruger KrasagakisDermatology Department, University Hospital of Heraklion, 71500 Heraklion, Greece.
Dimitris TsoukalasMetabolomic Medicine, Health Clinics for Autoimmune and Chronic Diseases, 10674 Athens, Greece.ORCID 0000-0001-6885-6209
Gottfried RudofskyClinic of Endocrinology and Metabolic Disorders, Cantonal Hospital Olten, Baslerstrasse 150, 4600 Olten, Switzerland.
Aristides TsatsakisLaboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-3824-2462
University of Crete · GRKantonsschule Olten · CHRFF-CMCC European Institute on Economics and the Environment · ITUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hashimoto's thyroiditis and psoriasis are inflammatory disorders that significantly impact patients' quality of life, stressing the need for novel biomarkers of early diagnosis. This randomized clinical trial (NCT04693936) aims to identify Hashimoto's thyroiditis' and psoriasis' metabolic biomarkers and to investigate the effect of environmental factors on the disease-related metabolic imprint and quality of life. Patients with Hashimoto's thyroiditis, patients with psoriasis, and healthy individuals aged 18-60 will be recruited, enrolled according to eligibility criteria (medical history, clinical thyroid markers and the PASI score) and randomized to two groups. The intervention group will receive a combination of nutraceuticals for 6 months as part of a Mediterranean diet, and the control group will follow their usual diet. Data will be collected at baseline and the end of the study, including metabolite levels, lifestyle and anthropometric measurements, adherence to the Mediterranean diet (through the Mediterranean Diet Score) and disease-specific quality of life (through the Thyroid Patient Report Outcome for Hashimoto's group, and the Dermatology Life Quality Index for the psoriasis group). This study will investigate metabolic biomarkers and related changes in Hashimoto's thyroiditis and psoriasis and evaluate the association of metabolic changes with dietary factors and quality of life.

Indexed as

epigenetic factorsfatty acidsHashimoto’smetabolic biomarkersmetabolomicsorganic acidspsoriasisquality of life

Identifiers

PMID35366263
PMCPMC8830459
OpenAlexW3172400155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.